The global pandemic of SARS-CoV-2, the causative viral pathogen of COVID-19, has driven
the biomedical community to action—to uncover and develop antiviral interventions. One …

For many decades, the design of new nucleoside analogs as potential therapeutic agents
focused on both sugar and nucleobase modifications. These nucleoside analogs rely on …

The ProTide technology is a prodrug approach developed for the efficient intracellular
delivery of nucleoside analogue monophosphates and monophosphonates. In this …

Hepatitis C virus (HCV) is a global health problem requiring novel approaches for effective
treatment of this disease. The HCV NS5B polymerase has been demonstrated to be a viable …

A decade ago, just five drugs were licensed for the treatment of viral infections. Since then,
greater understanding of viral life cycles, prompted in particular by the need to combat …

Phosphonic acids are rarely found in drug candidate molecules, despite the potential of this
functional group to provide unique binding interactions with a target enzyme or receptor …

An isopropylalaninyl monoamidate phenyl monoester prodrug of tenofovir (GS 7340) was
prepared, and its in vitro antiviral activity, metabolism, and pharmacokinetics in dogs were …

A substantial portion of metabolism involves transformation of phosphate esters, including
pathways leading to nucleotides and oligonucleotides, carbohydrates, isoprenoids and …

The human multidrug resistance proteins MRP4 and MRP5 are organic anion transporters
that have the unusual ability to transport cyclic nucleotides and some nucleoside …

Prodrug technologies aimed at delivering nucleoside monophosphates into cells (protides)
have proved to be effective in improving the therapeutic potential of antiviral and anticancer …